- Home
- LNKB vs ALLO Comparison
LNKB vs ALLO Comparison
Compare LNKB & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- ALLO
- Stock Information
- Founded
- LNKB 2018
- ALLO 2017
- Country
- LNKB United States
- ALLO United States
- Employees
- LNKB N/A
- ALLO N/A
- Industry
- LNKB
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LNKB
- ALLO Health Care
- Exchange
- LNKB Nasdaq
- ALLO Nasdaq
- Market Cap
- LNKB 270.4M
- ALLO 252.9M
- IPO Year
- LNKB N/A
- ALLO 2018
- Fundamental
- Price
- LNKB $7.05
- ALLO $1.45
- Analyst Decision
- LNKB Strong Buy
- ALLO Buy
- Analyst Count
- LNKB 1
- ALLO 12
- Target Price
- LNKB $9.00
- ALLO $8.80
- AVG Volume (30 Days)
- LNKB 60.5K
- ALLO 2.9M
- Earning Date
- LNKB 10-27-2025
- ALLO 11-06-2025
- Dividend Yield
- LNKB 4.26%
- ALLO N/A
- EPS Growth
- LNKB N/A
- ALLO N/A
- EPS
- LNKB 1.01
- ALLO N/A
- Revenue
- LNKB $121,982,000.00
- ALLO N/A
- Revenue This Year
- LNKB $18.26
- ALLO N/A
- Revenue Next Year
- LNKB N/A
- ALLO $100.00
- P/E Ratio
- LNKB $6.98
- ALLO N/A
- Revenue Growth
- LNKB 79.01
- ALLO N/A
- 52 Week Low
- LNKB $6.09
- ALLO $0.86
- 52 Week High
- LNKB $7.98
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- LNKB 44.84
- ALLO 64.79
- Support Level
- LNKB $6.92
- ALLO $1.29
- Resistance Level
- LNKB $7.25
- ALLO $1.43
- Average True Range (ATR)
- LNKB 0.20
- ALLO 0.07
- MACD
- LNKB -0.03
- ALLO 0.02
- Stochastic Oscillator
- LNKB 26.23
- ALLO 78.17
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.